Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06008808 · ClinicalTrials.gov registry record · Phase 1

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

A Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 1
Development phase
41
Enrollment target
1
Study location

NCT06008808 is a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 41 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06008808, a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 1
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leukemia (GVL) effect. The hypothesis of this study is that JAK inhibition with and without CTLA-4 Ig with haploidentical HCT may mitigate GVHD and cytokine release syndrome while retaining the GVL effect and improving engraftment.

Conditions Studied

Graft-Versus-Host Disease Graft Vs Host Disease

Interventions

  • DRUG Abatacept
  • DRUG Ruxolitinib

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2024-05-07
Est. Completion 2026-12-11
Phase Phase 1

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06008808

The ClinicalTrials.gov registry entry for NCT06008808 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (50% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Abatacept is the first listed.

NCT06008808 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06008808 about?

NCT06008808 is a clinical study titled "Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation". Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readil...

What is the current status of trial NCT06008808?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-05-07. Estimated completion is 2026-12-11.

What conditions does trial NCT06008808 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, Graft Vs Host Disease.

What interventions are being tested in trial NCT06008808?

The interventions under investigation include: Abatacept (DRUG), Ruxolitinib (DRUG).

Who is sponsoring clinical trial NCT06008808?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06008808 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graft-Versus-Host Disease

All registered trials for this condition

Graft Vs Host Disease

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.